



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

APR 22 2002

RECEIVED

In re the application of: Wilhelm Amberg, *et al.*

Serial No.: 09/757,142

Filed: January 9, 2001

For: *ANTINEOPLASTIC PEPTIDES*

Attorney Docket No.: BBI-6026CPCN

(formerly 2079.1009-001)

Group Art Unit: 1627

Examiner: Celsa, Bennett M

Commissioner for Patents
Washington, D.C. 20231

sla
4-28-02

Certificate of First Class Mailing (37 C.F.R. 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

March 26, 2002
Date

By:

Peter C. Lauro
Peter C. Lauro, Esq.
Reg. No. 32,360
Attorney for Applicants

**AMENDMENT AND RESPONSE TO NOTICE TO COMPLY
WITH SEQUENCE RULES 37 C.F.R. §§ 1.821-1.825**

Dear Sir:

This document is submitted in response to the Notice to Comply with Sequence Rules 37 C.F.R. §§ 1.821-1.825 (Paper No. 5) mailed from the United States Patent and Trademark Office on February 26, 2002, a copy of which is enclosed. Please amend the application as follows:

In The Specification:

Please delete Table I at Page 24, lines 19 to 25, and insert the following:

Table I – Sequence Identification of Compounds Prepared According to Examples 1 and 2

Compound Number(s)

Sequence ID Number

1-56, 58-72, 75, 77, 79, 80, 82
87-94, 96, 97, 99-101, 104-151
73, 74, 83-86, 95
57, 76, 81, 102
78, 98, 103

SEQ ID NO: 1
SEQ ID NO: 2
SEQ ID NO: 3
SEQ ID NO: 4

al